Long-term clinical and cost-effectiveness of a fully automated digital cognitive behavioural therapy for insomnia: 2-year follow-up of a single-blind, superiority, randomised controlled trial

Background We evaluated the long-term clinical and cost-effectiveness of fully automated digital cognitive behavioural therapy for insomnia (dCBT-I) or online patient education (PE) in the Norwegian general population.Methods A parallel-group, participant-blinded, superiority randomised controlled trial in self-referred adults with significant insomnia symptoms (Insomnia Severity Index [ISI] 12).Participants completed automated screening prior to randomisation and outcomes were assessed over 2 years.The primary outcome (9-week clinical effectiveness) has been published.We now report intention-to-treat analyses from the 6-month and 2-year followups.Incremental cost-effectiveness ratio (ICER), with non-parametric bootstrapping, summarized the betweengroup societal costs in 2019 Euros, and quality-adjusted life years (QALYs).The trial was preregistered at ClinicalTrials.gov(NCT02558647) and followed a prespecified protocol.Findings 1720 participants (1167 [67.8%] female; mean age 44.4) were randomised between February 26, 2016, and July 1, 2018 (867 to dCBT-I vs. 853 to PE).The final follow-up included 587/1720 (34.1%) participants (dCBT-I = 315; PE = 272), a median of 28.3 months (IQR 22.6 to 34.0) after baseline.At 2-year follow-up the mean ISI was 10.7 (SD 5.9) in the dCBT-I group and 13.4 (5.9) in the PE group (estimated difference: -1.77 [95% CI: -2.65 to -0.90]; Cohen's d= -0.43).The dCBT-I group reported -278 [95% CI: -1413 to 858] lower costs and 0.025 QALYs gained [95% CI: 0.010 to 0.041] compared with PE, yielding a 94% probability of cost-effectiveness at 0 willingness-to-pay (ICER: -10,973 per QALY gained).No harms or adverse events were reported.Interpretation Compared with online PE, fully automated, low-threshold dCBT-I demonstrates greater short-term (9 week) and longer-term improvements (2 years) in insomnia severity and is likely cost-effective over the 2-year horizon.However, effects attenuated over time and long-term certainty is limited by attrition.

Authors

Institutions

Publication Details

Journal
The Lancet Regional Health - Europe
Published
2026-05-08
DOI
https://doi.org/10.1016/j.lanepe.2026.101691
Primary Topic
Sleep and related disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term clinical and cost-effectiveness of a fully automated digital cognitive behavioural therapy for insomnia: 2-year follow-up of a single-blind, superiority, randomised controlled trial

Håvard Kallestad, Vidar Halsteinli, Daniel Vethe, J Scott et al.
The Lancet Regional Health - Europe
Sleep and related disorders
article

Long-term clinical and cost-effectiveness of a fully automated digital cognitive behavioural therapy for insomnia: 2-year follow-up of a single-blind, superiority, randomised controlled trial

Håvard Kallestad, Vidar Halsteinli, Daniel Vethe, J Scott, Børge Sivertsen, Øystein Vedaa, Knut Langsrud, Lee M. Ritterband, Otto Robert F Smith, Simen B. Saksvik, Gunnar Morken, Cecilie L. Vestergaard, Zareen A. Khan
article en

Abstract

Background We evaluated the long-term clinical and cost-effectiveness of fully automated digital cognitive behavioural therapy for insomnia (dCBT-I) or online patient education (PE) in the Norwegian general population.Methods A parallel-group, participant-blinded, superiority randomised controlled trial in self-referred adults with significant insomnia symptoms (Insomnia Severity Index [ISI] 12).Participants completed automated screening prior to randomisation and outcomes were assessed over 2 years.The primary outcome (9-week clinical effectiveness) has been published.We now report intention-to-treat analyses from the 6-month and 2-year followups.Incremental cost-effectiveness ratio (ICER), with non-parametric bootstrapping, summarized the betweengroup societal costs in 2019 Euros, and quality-adjusted life years (QALYs).The trial was preregistered at ClinicalTrials.gov(NCT02558647) and followed a prespecified protocol.Findings 1720 participants (1167 [67.8%] female; mean age 44.4) were randomised between February 26, 2016, and July 1, 2018 (867 to dCBT-I vs. 853 to PE).The final follow-up included 587/1720 (34.1%) participants (dCBT-I = 315; PE = 272), a median of 28.3 months (IQR 22.6 to 34.0) after baseline.At 2-year follow-up the mean ISI was 10.7 (SD 5.9) in the dCBT-I group and 13.4 (5.9) in the PE group (estimated difference: -1.77 [95% CI: -2.65 to -0.90]; Cohen's d= -0.43).The dCBT-I group reported -278 [95% CI: -1413 to 858] lower costs and 0.025 QALYs gained [95% CI: 0.010 to 0.041] compared with PE, yielding a 94% probability of cost-effectiveness at 0 willingness-to-pay (ICER: -10,973 per QALY gained).No harms or adverse events were reported.Interpretation Compared with online PE, fully automated, low-threshold dCBT-I demonstrates greater short-term (9 week) and longer-term improvements (2 years) in insomnia severity and is likely cost-effective over the 2-year horizon.However, effects attenuated over time and long-term certainty is limited by attrition.

The Lancet Regional Health - EuropeVol. 66
Norwegian Institute of Public Health (NO), Norwegian University of Science and Technology (NO), St Olav's University Hospital (NO), NLA University College (NO), Fonna Hospital Trust (NO), Newcastle University (GB)
Helse Midt-Norge, Norges Forskningsråd
Openalex Percentile: Top 7%
Sleep and related disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.